Articles tagged with Heart Failure
Researchers developed an injectable hydrogel containing fish swim bladder components to repair damaged heart tissue, showing enhanced cardiac cell adhesion and stretching. The treatment also promoted new blood vessel formation and reduced inflammation in a rat model of ischemic heart failure.
A recent study published in the International Journal of Cardiology analyzed data from multiple clinical trials to assess the therapeutic impact of pulmonary artery denervation (PADN) on pulmonary hypertension patients. PADN showed significant reductions in mean right atrial pressure, mean pulmonary artery pressure, and pulmonary vascu...
A large long-term study found a significant association between hearing loss and increased risk of developing heart failure. The psychological distress caused by hearing impairment played a key role in this observed association, with socially isolated individuals and those experiencing anxiety and depression facing a heightened risk.
A study of nearly 30,000 adults found that heart failure is associated with a significant decrease in cognition at diagnosis and rapid decline over time. Adults with heart failure reach the threshold for meaningful decline in global cognition nearly six years earlier than those without it.
The device uses AI technology to detect potential heart problems and provides real-time health insights. It has multiple points touching the skin near the heart, allowing for more accurate tracking even during movement.
The SUMMIT trial shows tirzepatide reduces the risk of cardiovascular death or worsening heart failure in patients with obesity, chronic kidney disease, and heart failure, while improving kidney function. Researchers found significant improvements in both patient groups with and without chronic kidney disease.
A large-scale study found that limiting fluid intake in patients with stable heart failure has no health benefits and may even cause increased thirst. Conversely, drinking more fluids without restriction did not lead to any negative outcomes, suggesting that fluid restrictions are unnecessary for these patients.
A minimally invasive procedure using a clip to repair the tricuspid valve significantly reduced symptom severity and decreased recurrent hospitalization for heart failure. The study found a 28% reduction in hospitalizations at two years, with improved safety and effectiveness compared to medical therapy alone.
A new mobile integrated health program delivered in-home visits from paramedic teams to people with heart failure did not significantly reduce hospital readmissions or improve health status compared to standard follow-up phone calls. However, the study found that women and younger patients may benefit more from this intervention.
The Finerenone Trial found that sudden death was the primary cause of higher cardiovascular mortality in patients with heart failure and mild or preserved ejection fractions. The study suggests that finerenone may not significantly impact cardiovascular mortality, but its effects on overall mortality are unclear.
A study found that intravenous iron supplementation resulted in a 20% lower risk of cardiovascular death or first heart failure hospitalization, as well as improved symptoms and quality of life. The benefits were most pronounced in the first year after treatment, suggesting a meaningful association between iron dosage and outcomes.
A large randomized controlled trial found no significant difference in health status between patients with restricted and unrestricted fluid intake. Despite this, patients on fluid restriction reported more thirst and had lower overall health scores at baseline compared to those with liberal fluid intake.
Early IABP use did not improve 60-day survival or transition patients to long-term treatment compared to standard medical care. The trial found that the device offered no additional benefit, leading to its early termination.
Ferric carboxymaltose did not significantly reduce time to first heart failure hospitalization or cardiovascular death in patients with heart failure and iron deficiency. The treatment also did not reduce total number of heart failure hospitalizations compared to placebo.
A study presented at the American College of Cardiology's Annual Scientific Session found that dapagliflozin significantly reduced the rate of worsening heart failure in elderly patients with heart failure undergoing transcatheter aortic valve replacement. The trial, called DapaTAVI, enrolled 1,257 patients and showed a 28% lower rate ...
A study published in JAMA Cardiology found that finerenone was effective in treating heart failure, regardless of the presence of atrial fibrillation. New-onset atrial fibrillation was linked to a substantially increased risk of adverse outcomes.
Researchers from Emory University are using the International Space Station to study cardiac cells and accelerate the development of cell-based regenerative therapies. The team's findings have led to multiple peer-reviewed publications and could significantly advance methods to produce cardiac cells for heart disease treatment.
The American Heart Association has launched a new certification program for hospitals dedicated to optimizing heart failure treatment, reducing readmissions. The Heart Failure Center Certification aims to enhance patient outcomes and promote evidence-based treatments.
Researchers found that gasdermin D promotes atrial arrhythmogenesis by facilitating the formation of pores in cell membranes and releasing cytokines. A mitochondrial-targeted therapy approach may prevent AF triggering, positioning gasdermin D as a promising therapeutic target.
People with heart failure who can travel outside their home without assistance are less likely to be hospitalized or die within a year. Life-space mobility, a measure of how far patients move in their communities, is a reliable marker of risk for adverse outcomes in chronic diseases.
TCT 2025 will take place October 25-28, 2025, at the Moscone Center in San Francisco, California. The event will feature acute interventions, breakthrough technologies, and cutting-edge research driving the next era of cardiovascular care.
A study found that women who underwent bilateral oophorectomy were more likely to develop heart failure later in life. The researchers suggest that early menopause may be a contributing factor to this increased risk, and recommend closer cardiovascular monitoring for women contemplating the procedure.
Researchers at the University of Virginia Health System have developed a computational tool called LogiRx that can predict how drugs will affect biological processes in the body. The tool has demonstrated its potential by identifying a promising candidate to prevent heart failure, a leading cause of death worldwide.
A recent study published in the European Journal of Preventive Cardiology found that older patients with heart failure who exercised regularly before hospitalization had better physical function and lower mortality. Regular exercise was linked to greater grip strength, higher gait speeds, and improved overall health outcomes.
A new study from Karolinska Institutet found that patients with heart failure who stop taking medications like RASi, ARNi, or MRA have a higher risk of heart-related death or hospitalization. Despite improved symptoms and pump function, continued medication is crucial to prevent complications.
Researchers have discovered a new way to stimulate cardiomyocyte proliferation, offering promising results in both human cardiac slices and live animals. This innovative approach targets calcium signaling pathways, potentially transforming the treatment landscape for patients suffering from heart failure.
Josep Rodés-Cabau takes over as Editor-in-Chief of Structural Heart: The Journal of the Heart Team, following Anthony N. DeMaria's retirement. Dr. Rodés-Cabau is a world-renowned expert in structural heart disease with extensive research and academic experience.
A recent study by Professor Mamas highlights the significant risk of cardiovascular diseases (CVD) in patients with cancer, particularly in aging populations. The review emphasizes the need for early diagnosis and regular monitoring to improve quality of life.
A new study published in the European Journal of Preventive Cardiology found that a type of diabetes medication called SGLT2 inhibitors can significantly lower the risk of heart failure and hospital visits related to heart failure in cancer patients. The benefits were particularly promising for breast cancer patients receiving anthracy...
The project aims to improve the quality of life for patients with end-stage heart failure and their caregivers through a nurse-led intervention. The study will also track hospitalization rates, patient well-being, and gain a better understanding of end-of-life care.
Preoperative anemia is a recognized risk factor for adverse outcomes in CABG, but it does not affect the long-term survival advantage associated with CABG. This study provides evidence that surgical intervention can still be beneficial for ICM patients despite preoperative anemia.
A retrospective cohort study from the University of Ottawa and Manitoba found Canadians with hypertension whose preferred language was spoken by their doctor were 36% less likely to have a major adverse cardiovascular event. Patients with language-accessible care had a 28% lower risk of death compared to those without such access.
Johnson & Johnson MedTech is celebrating the inaugural National Heart Recovery Awareness Day to raise awareness of heart health and innovative medical technology. The company's Impella platform has been used to treat over 330,000 patients globally, enabling patients to recover their native heart and improve their quality of life.
A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.
A study published in Nature Cardiovascular Research found that tricaprin improved long-term survival and recovery from heart failure in patients with triglyceride deposit cardiomyovasculopathy. The supplement reversed structural changes and improved heart muscle function, leading to higher survival rates compared to controls.
A new mechanical heart pump, BrioVAD, is being tested against the current standard, HeartMate 3, in a national study. The trial aims to enroll 780 participants with advanced heart failure and will compare the two devices head-to-head.
The article proposes clear career paths and standardized training pathways in interventional heart failure, aiming to enable specialists to drive innovation and improve outcomes. It highlights the need for a formalized approach to training and career development in this field.
A new Northwestern Medicine study reveals that macrophages in newborns use a process called efferocytosis to produce thromboxane, which triggers the production of a bioactive lipid that signals heart muscle cells to divide and regenerate. This process is less effective in adults, leading to scar-tissue buildup and often heart failure.
A study published in Nature Medicine found that AI algorithm 'DeepRhythmAI' outperformed human technicians in analyzing long-term ECG recordings, detecting severe arrhythmias with 14 times fewer missed diagnoses. The AI algorithm achieved near-perfect sensitivity and ruled out severe arrhythmia with 99.9% confidence.
The American Heart Association reports that Black communities face disproportionately higher risk of heart disease, stroke, and hypertension, leading to poorer survival outcomes. Hands-Only CPR training and heart health education are critical to addressing these disparities and advancing equitable health solutions.
Researchers at Tampere University developed a new method to detect congestive heart failure using inter-beat intervals measured by smartwatches and heart rate monitors. The accuracy of the method was found to be 90% in distinguishing patients with congestive heart failure from healthy control subjects.
A large genetic dataset and multi-omics approach identified 58 novel drug targets for both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The study highlights the importance of developing targeted therapies for both subtypes, which have limited therapeutic options.
The Cardiovascular Research Foundation will host THT 2025, showcasing late-breaking clinical science presentations on transcatheter approaches to managing a wide spectrum of heart failure patients. Four dedicated sessions feature exclusive first-release data from pivotal studies and dynamic discussions on controversies in clinical trials.
The International Society for Health and Lung Transplantation (ISHLT) has re-launched the Global IMACS Registry to collect data on patients with durable mechanical circulatory support devices. The registry aims to advance MCS therapy and improve patient outcomes globally.
A new study from the University of Birmingham found that digoxin is more effective than beta-blockers in reducing adverse events and hospital admissions for older patients with atrial fibrillation. This could lead to significant cost savings for the UK National Health Service, estimated at £102 million per year.
Researchers have identified ALPK2 as a potential therapeutic target for treating heart failure with preserved ejection function (HFpEF). The enzyme is believed to prevent stiff heart conditions through regulating the TPM1 gene. This discovery offers new hope for developing treatment options targeting ALPK2.
A cross-sectional study found that TV football game food ads are often high in sodium, calories, and fat content. This can pose a risk to adults with pre-existing heart conditions, who may be vulnerable to dietary deviations due to frequent exposure to advertising.
The American Heart Association has launched a $3 million initiative to create nationwide education on advanced heart failure treatment options. The goal is to bridge critical gaps in care and improve patient outcomes, particularly for populations with limited access to healthcare resources.
A study of 252 patients who underwent the Ross procedure found that survival rates were 95.8% at 5 years, 94.3% at 10 years, and 90.3% at 20 years. The procedure offers excellent long-term survival rates with low risk of re-intervention, making it an alternative to mechanical valve replacement.
The summit features live case demonstrations, interactive debates, hands-on training, and the latest evidence-based practices in structural heart care. Attendees will witness innovation in action, exploring breakthroughs in surgical techniques, transcatheter interventions, and personalized treatment strategies.
Researchers found that brief ozone exposure reduces blood oxygen saturation, triggers hypoxia-related biomarkers, and increases arterial stiffness. Ozone pollution is a worldwide health issue, linked to increased risk of cardiovascular diseases.
Research published in the European Heart Journal found that people with high amounts of intermuscular fat are more likely to develop coronary microvascular dysfunction and future serious heart disease. The study's lead author suggests that existing measures of obesity may not be accurate for all individuals, particularly women.
University of Birmingham researchers have been awarded a grant to study the mechanisms driving early cardiac dysfunction in CKD. The study aims to identify interventions that can reverse or prevent heart disease in its earliest stages.
A nationwide cohort study in Korea found that postdiagnosis weight gain is associated with an increased risk of heart failure after breast cancer development. Effective weight intervention can protect cardiovascular health, particularly within the first few years after diagnosis.
Researchers from the University of Maryland School of Medicine analyzed the second patient to receive a genetically-modified pig organ, identifying key factors contributing to rejection and highlighting areas for improvement. The study provides valuable insights into how to prevent graft failure in future transplants.
Researchers document five cases of parvovirus B19-induced myocarditis in preschoolers from northern Greece, highlighting the virus's unique impact on endothelial cells. The study emphasizes the importance of quick diagnosis and treatment to reduce mortality and morbidity in children.
Researchers found that injecting infarcted pig hearts with specially bioengineered cells significantly decreased the infarct area and improved heart function. The therapy worked by stimulating the proliferation of endogenous pig cardiomyocytes, which had previously been unable to divide in adult hearts.
Exposure to triclocarban, a common antibacterial agent, promotes myocardial hypertrophy in human cardiac organoids. The study found that TCC interferes with endothelial cell metabolism, leading to nitrosative stress and inflammation. This new mechanism suggests a potential treatment target for myocardial hypertrophy.
A research team led by a physician-scientist found that artificial heart patients can regenerate heart muscle cells, which may lead to new ways to treat and potentially cure heart failure. The study showed that these patients' hearts regenerate muscle cells at more than six times the rate of healthy hearts.
A new study reveals the COVID-19 pandemic led to a sharp decline in hospital visits for acute coronary syndrome, particularly among older adults and women. The research emphasizes the need for targeted interventions to ensure access to critical care during future emergencies.